| Bioactivity | Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells[1]. |
| Name | Englumafusp alfa |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Antonio Tapia-Galisteo, et al. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023 Jul 27;16(1):83. [2]. George Fromm, et al. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists. Front Immunol. 2023 Sep 19:14:1236332. |